IVIg– A newly approved therapeutic option for the treatment of adult dermatomyositis

Dr. Rohit Aggarwal educates us about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The successful ProDERM Study resulted in the first and only FDA-approved IVIg therapy for DM in adults.

Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with a characteristic skin rash and progressive proximal muscle weakness.

Dr. Rohit Aggarwal is a professor of medicine at the University of Pittsburgh and medical director of the Arthritis and Autoimmunity Center at the University of Pittsburgh Medical Center and he is the co-director of the UPMC Myositis Center. His research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease.

Myositis Support & Understanding and Octapharma USA are proud to co-sponsor this exciting educational program.

If you have questions you can reach out to the Octapharma Support Center at 1-800-554-4440

** View the slideshow and more on the webinars page on our website at https://understandingmyositis.org/ivig-newly-approved-therapeutic-option-adult-dermatomyositis/